Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: AMCR stock price vs NTLA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NTLA's multiple
Needs NTLA P/E.
Implied fair value · at AMCR's multiple
Needs EPS (TTM) is negative, AMCR P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMCR FY 2026 (ended Jun 30, 2026) · NTLA FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
AMCOR PLC · implied price per share
Bear
$18.65
Base
$21.94
Bull
$25.23
INTELLIA THERAPEUTICS, INC. · implied price per share
Bear
$1.08
Base
$1.27
Bull
$1.46
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.19x
0.16x
Net debt / EBITDA
Leverage against operating earnings
3.62x
0.85x
Cash and equivalents
Liquid reserves on the balance sheet
$1.12B
$449.88M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$14.00B
$106.36M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe AMCR can sustain its current margins and earnings while the market normalizes the valuation comparison away from NTLA’s loss-making profile, then hold or accumulate on weakness because AMCR already trades near its historical range and above the DCF range despite being profitable.
The valuation gap is extreme: AMCR trades at 1.4x P/S versus NTLA at 36.3x P/S, and the stated NTLA-implied price of $236.05 implies 424.6% upside from $45.00. However, that implied upside is driven by a highly distorted cross-company comparison, since NTLA has negative margins and negative earnings, making the ratio-based NTLA benchmark unreliable.
Supporting Metrics
